Figure 6.

IGF2BP1-promoted invasive growth is abolished by combined SRCi/MEKi treatment. (A–H) Spheroid growth (A, C, E, F) or invasion (B, D, G, H) of GFP (controls) or IGF2BP1 over-expressing ES-2 cells was monitored and analysed as in Fig. (1J, K). All treatments at indicated concentrations were performed on pre-formed (24 h) spheroids for indicated time and concentrations. Error bars indicate SE (A, B). (I, J) iRFP-labelled GFP or IGF2BP1 over-expressing ES-2 cells pre-treated with saracatinib (3 µM) and selumetinib (3 µM) or DMSO for 48 h, were IP injected into nude mice with compounds at indicated concentrations. Tumour growth of five mice per conditions (I) was monitored and quantified (J) by infra-red imaging of the abdominal region 2 weeks post injection. Statistical significance was tested by Student’s T-test or Mann-Whitney rank-sum test. *, p < 0.05; **, p < 0.01; ***, p < 0.001